Listerine with fluoride meeting postponed
This article was originally published in The Rose Sheet
Executive Summary
"Feedback" meeting on OTC anticaries drug products monograph slated for June 18 in Rockville, MD will be rescheduled, probably within a month, according to FDA's division of OTC Drug Products. Meeting is part of Pfizer's efforts to amend the monograph to allow a mouthrinse combining essential oils and sodium fluoride (1'The Rose Sheet" June 10, 2002, p. 5). FDA says it needs more time to review relevant materials...
You may also be interested in...
Listerine With Fluoride Development Continues With “Feedback” Meeting
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.